KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Revenue (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Revenue data on record, last reported at $11.8 million in Q3 2025.

  • For Q3 2025, Revenue fell 51.13% year-over-year to $11.8 million; the TTM value through Sep 2025 reached $62.6 million, down 32.79%, while the annual FY2024 figure was $98.4 million, 9.22% up from the prior year.
  • Revenue reached $11.8 million in Q3 2025 per NKTR's latest filing, up from $11.2 million in the prior quarter.
  • Across five years, Revenue topped out at $29.2 million in Q4 2024 and bottomed at $10.5 million in Q1 2025.
  • Average Revenue over 5 years is $21.9 million, with a median of $23.6 million recorded in 2022.
  • Peak YoY movement for Revenue: plummeted 53.24% in 2021, then grew 22.15% in 2024.
  • A 5-year view of Revenue shows it stood at $25.0 million in 2021, then dropped by 11.94% to $22.0 million in 2022, then increased by 8.45% to $23.9 million in 2023, then grew by 22.15% to $29.2 million in 2024, then plummeted by 59.59% to $11.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $11.8 million in Q3 2025, $11.2 million in Q2 2025, and $10.5 million in Q1 2025.